Cybin News

Cybin's CYB003 Shows Promise in MDD Treatment, Justifying Buy Rating

TipRanksMar 14 19:18

Buy Rating Affirmed for Cybin on Promising CYB003 Clinical Data and Strategic FDA Designations

TipRanksMar 13 23:35

Cybin Analyst Ratings

BenzingaMar 13 23:30

Cybin Analyst Ratings

BenzingaFeb 16 01:39

Promising Futures for Cybin's Psychedelic Treatments: A Buy Rating Analysis

TipRanksFeb 16 00:55

Oppenheimer Sticks to Their Buy Rating for Cybin (CYBN)

TipRanksJan 9 20:54

Buy Rating Affirmed for Cybin Based on Advancements in Psychedelic Treatments and Optimistic Valuation

TipRanksJan 5 00:05

Analysts' Opinions Are Mixed on These Healthcare Stocks: Cybin (CYBN), Nevro Corp (NVRO) and Biogen (BIIB)

TipRanksDec 1, 2023 21:02

Analysts Conflicted on These Healthcare Names: Protara Therapeutics (TARA), Cybin (CYBN) and Roche Holding AG (OtherRHHVF)

TipRanksDec 1, 2023 19:40

Analysts Offer Insights on Healthcare Companies: Cybin (CYBN), ADMA Biologics (ADMA) and Halozyme (HALO)

TipRanksNov 17, 2023 19:20

HC Wainwright & Co. Maintains Buy on Cybin, Lowers Price Target to $5

BenzingaNov 17, 2023 19:14

Cybin Analyst Ratings

BenzingaNov 17, 2023 19:13

Compelling Factors Bolster Buy Rating for Cybin Inc.: Emphasis on Promising Phase 2 Trial Results and Strategic Acquisitions

TipRanksNov 3, 2023 02:11

Promising Phase 2 Results and Financial Projections Bolster Buy Rating for Cybin: An Analysis by Patrick Trucchio

TipRanksOct 31, 2023 21:26

HC Wainwright & Co. Reiterates Buy on Cybin, Maintains $10 Price Target

BenzingaOct 31, 2023 21:22

Cybin Analyst Ratings

BenzingaOct 31, 2023 21:21

Cybin's Promising Developments and Emerging Data: A Comprehensive Analysis Justifying Buy Rating and $10 Price Target

TipRanksOct 2, 2023 23:46

What 11 Analyst Ratings Have To Say About Cybin

BenzingaSep 2, 2023 00:00

Canaccord Genuity Reiterates Buy on Cybin, Maintains $5 Price Target

BenzingaSep 1, 2023 22:33

Cybin Analyst Ratings

BenzingaSep 1, 2023 22:32